Scarica l'app Stockscreener
88.11
0.27%
0.24
Dopo l'orario di chiusura:
88.15
0.04
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$87.87
Aprire:
$88.24
Volume 24 ore:
13.47M
Relative Volume:
0.95
Capitalizzazione di mercato:
$235.20B
Reddito:
$64.17B
Utile/perdita netta:
$17.12B
Rapporto P/E:
13.09
EPS:
6.73
Flusso di cassa netto:
$18.10B
1 W Prestazione:
-6.29%
1M Prestazione:
-1.42%
6M Prestazione:
-22.09%
1 anno Prestazione:
-29.80%
Intervallo 1D:
$87.31
$89.32
Intervallo di 1 settimana:
$87.08
$95.16
Portata 52W:
$81.04
$134.63
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Confronta MRK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
88.11 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
826.76 | 742.57B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.30 | 356.10B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.72 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
71.73 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy? - Insider Monkey
Why Summit Therapeutics Stock Slipped Today - The Motley Fool
Jim Cramer on Merck (MRK): “I Like It at This Level – But I Like Bristol-Myers Even More!” - Yahoo Finance
Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook - Seeking Alpha
Merck wins European Commission approval for pneumonia vaccine Capvaxive - Seeking Alpha
Merck & Co. (MRK) Stock: Pharmaceutical Giant Signs $2 Billion Heart Disease Drug Deal - MoneyCheck
European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) - Marketscreener.com
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck Receives European Approval for Streptococcal Pneumonia Vaccine - Marketscreener.com
Merck Gets European Commission Approval of Capvaxive Vaccine - Marketscreener.com
Why Merck & Co. Inc. (MRK) Performed Worst On Tuesday? - Insider Monkey
GME, KBSX, MRK, UPS, TSLA: Top 5 Trending Stocks TodayGameStop (NYSE:GME) - Benzinga
Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset - News & Insights
Is Merck & Co. Inc. (MRK) The Best Defensive Stock Amid Market Volatility? - Insider Monkey
Merck Makes Bold $2B Bet on Chinese Cardio Drug - USA Herald
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MSN
For nearly $2B, Jiangsu Hengrui licenses heart drug to Merck - BioWorld Online
Merck Betting Up To $2B On China-Developed Cardio Drug - Law360
Merck & Co Inc (MRK) Trading Down 3.66% on Mar 25 - GuruFocus.com
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment - Benzinga
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug Candidate - Marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck inks $2B licensing deal with Jiangsu Hengrui (MRK:NYSE) - Seeking Alpha
Merck Will Pay Up to $2 Billion for Chinese Heart Drug Rights - Bloomberg
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Merck buys rights to heart disease drug in latest China deal - Marketscreener.com
Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug - Marketscreener.com
Merck Enters Exclusive License Agreement For HRS-5346 From Jiangsu Hengrui Pharmaceuticals - Marketscreener.com
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - Business Wire
Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Merck & Co. sees ratings upgrade to Aa3 by Moody’s Ratings - Investing.com
Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (Fed. Cir. 2025) - JD Supra
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein - GlobeNewswire
Is Merck & Co. (MRK) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
MRK LAWSUIT ALERT: The Gross Law Firm Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
Merck & Co. (MRK): Among Stocks Insiders Were Piling Into Recently - Yahoo Finance
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - PR Newswire
Lyophilized Product Market to Witness Remarkable Growth with - openPR
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRK - PR Newswire
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
Merck & Co., Inc. (MRK): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):